期刊文献+

新型N-[2-(取代苯并噻唑-2-氨基甲酰基)苯基]取代氟基苯甲酰胺的合成及其抗癌活性 被引量:4

Synthesis and Anticancer Activities of Novel N-[2-(substituted benzothiazol-2-carbamoyl)phenyl] substituted-fluoro-benzamides
下载PDF
导出
摘要 2,4-二氟苯甲酸或2-氟苯甲酸与二氯亚砜经酰氯化反应,再与邻氨基苯甲酸反应后在醋酸酐中闭环,最后与取代苯并噻唑胺反应合成了9个新型的N-[2-(取代苯并噻唑-2-氨基甲酰基)苯基]取代氟基苯甲酰胺(6a~6i),其结构经1H NMR,13C NMR,IR和元素分析表征。采用MTT法对6a~6i进行抑制PC3癌细胞体外活性测试,结果表明6a~6i具有不同程度的抑制PC3癌细胞活性,其中10μmol.L-16b对PC3的抑制率为69.9%。 Nine novel N-[ 2-( substituted benzothiazol-2-carbamoyl)phenyl] substituted-fluoro- benzamides (6a - 6i) were sythesized by the acyl chlorination of 2-fluorobenzoic acid or 2,4-difluorobenzoic acid with thionyl chloride, then coupled with 2-aminobenzoic acid, cyclized in the presence of acetic anhydride, in the end coupled with substituted benzo[ d] thiazol-2-amine. The structures were characterized by 1H NMR, 13C NMR, IR and elemental analysis. Preliminary bioassay tests indicated that 6a - 6i exhibited antitumor activities to PC3 cells in vitro by MTT method. The antiproliferation activity of 6b( 10 μmol·L^-1) to PC3 ceils was 69.9%.
出处 《合成化学》 CAS CSCD 北大核心 2012年第3期281-285,共5页 Chinese Journal of Synthetic Chemistry
基金 贵州省教育厅自然科学研究项目(黔教科2010090) 贵州省教育厅质量工程项目{黔教高[2011]278}
关键词 双酰胺 苯并噻唑 抗癌活性 合成 diamide benzothiazol fluorine anticancer activity synthesis
  • 相关文献

参考文献15

  • 1Finerty M J, Bingham J P, Hartley J A, et al. Azino- mycin bisepoxides containing rigid aromatic linkers: Synthesis, cytotoxicity and DNA interstrand cross-link- ing activity [ J ]. Tetrahedron Letters, 2009,50 ( 26 ) : 3648 - 3650.
  • 2Mahindroo N, Punchihewa C, Fujii N. Hedgehog-gli signaling pathway inhibitors as anticancer agents [ J ]. Journal of Medicinal Chemestry,2009,52 ( 13 ) : 3829 - 3845.
  • 3Suzuki N, Suzuki T, Ota Y, et al. Design,synthesis, and biological activity of boronlc acid-based histone deacetylase inhibitors [ J ]. Journal of Medicinal Cheme- stry ,2009 ,52 (9) : 2909 - 2922.
  • 4Castellano S, Milite C, Ragno R, et al. Design, syn- thesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 ( AMI-1 ) [ J ]. Journal of Medicinal Chemestry, 2010,5 ( 3 ) : 398 - 414.
  • 5Yu M, Lizarzaburu M, Beckmann H, et al. Identifica- tion of piperaziae-hlsamide GHSR axttagonists for the treatment of obesity [ J ]. Bioorganic & Medicinal Chemistry Letters ,2010,20(5 ) : 1758 - 1762.
  • 6Descoteaux C, Leblanc V, Brasseur K, et al. Synthe- sis of D- and L-tyrosine-chlorambucil analogs active a- gainst breast cancer cell lines [ J ]. Bioorganic & Me- dicinal Chemistry Letters ,2010,20 (24) :7388 - 7392.
  • 7Koci J, Klimesova V, Waisser K, et al. Heterocyclic benzazole derivatives with antimyeobacterial in vitro activity [ J ]. Bioorganie & Medicinal Chemistry Let- ters ,2002,12(22) :3275 - 3278.
  • 8Hutchinson I, Chua M S, Browne H L, et al. Synthe- sis and in vitro biological properties of fluorinated 2- (4-aminophenyl) benzothiazoles [ J ]. Journal of Medici- nal Chemestry,2001,44(9) :1446 - 1455.
  • 9Bradshaw T D, Westwell A D. The development of the antitumor benzothiazole prodrug, phortress, as a clini- cal candidate[ J ]. Current Topics in Medicinal Chemis- try ,2004 ,U( 13 ) : 1009 - 1021.
  • 10Zhang L, Biamonte M, Busch D. 7-Substituted benzothiazolothio and pyridinothiazolothio purines as potent heat shock protein 90 inhibitors [ J ]. Journal of Medicinal Chemestry, 2006, 49 ( 17 ) : 5352 - 5362.

同被引文献40

  • 1普建新,羊晓东,赵静峰,李翠红,李良.藏药心叶兔儿风挥发油成分分析[J].云南大学学报(自然科学版),2004,26(4):345-347. 被引量:14
  • 2洪艳平,宋宝安,吴平,颜贤仔,刘楠.苯并噻唑类农药生物活性研究进展[J].安徽农业科学,2005,33(7):1254-1257. 被引量:27
  • 3中华人民共和国国家药典委员会.中华人民共和国药典(一部)[S].北京:中国医药科技出版社,2010:附录ⅩD.
  • 4Jemal A, Bray F,Center M M,et ul. Global cancer statistics [ J ]. CA - Cancer J Clin, 2011,61 ( 2 ) :69 - 90.
  • 5Sreenath V, Sharma S V, Daphne W, et al. Epidermal growth factor re- ceptor mutations in lung cancer [ J ] Nat Rev Cancer, 2007,7 (3) : 169 - 181.
  • 6Bimhaum A, Ready New. Gefitinib therapy for non - small cell lung cancer [ J]. Curt Treat Options Onco1,2005,6( 1 ) :75 - 81.
  • 7Mok T S. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarci- noma [J]. N Engl J Med,2009,361 (10) :947 -957.
  • 8Zhou C, Wu Y L, Chen G, et al. Erlotinib versus ehemotherapy as first - line treatment for patients with advanced EGFR mutation - positive non - small - cell lung cancer ( OPTIMAL, CTONG - 0802 ) : a multi - centre,open - label, randomised, phase 3 study [ J ]. Lancet Oncol, 2011,12:735 - 742.
  • 9Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemo- therapy as first - line treatment for European patients with advanced EG- FR nmtation - positive non - snmll - cell lung cancer (EURTAC) : a muhicentre,open - label, randomised phase3 trial [ J ]. Lancet Oncol, 2012,13:239 - 246.
  • 10Q zhou, J shcn, J shentu, et al. A phase I/II a study of icotinib hydrochloride,a novel oral EGFR - TK1, to evaluate its safety, toler- ance, and preliminary efficacy in advanced NSCLC patients in china [ J ]. J Clin Onco1,2010,28,15s ( sl ) :7574.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部